LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Начало・Списък с акции・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Затворен

15.24 0.73

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

14.59

Максимум

15.45

Ключови измерители
By Trading Economics
Приходи	-6.4M -20M
Продажби	-807K 71M
EPS	-0.13
Марж на печалбата	-28.24
Служители	624
EBITDA	-7.9M -14M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+33.14% upside

Дивиденти
By Dow Jones
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-95M 2.2B
Предишно отваряне	14.51
Предишно затваряне	15.24

Adaptive Biotechnologies Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.06.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1.06.2026 г., 23:38 ч. UTC

Придобивния, сливания и поглъщания

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1.06.2026 г., 23:37 ч. UTC

Пазарно говорене

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1.06.2026 г., 23:01 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.06.2026 г., 23:01 ч. UTC

Пазарно говорене

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1.06.2026 г., 22:08 ч. UTC

Придобивния, сливания и поглъщания

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1.06.2026 г., 22:01 ч. UTC

Придобивния, сливания и поглъщания

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1.06.2026 г., 22:01 ч. UTC

Придобивния, сливания и поглъщания

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1.06.2026 г., 21:55 ч. UTC

Придобивния, сливания и поглъщания

Greg Abel's Week Is Off to Quite a Start -- WSJ

1.06.2026 г., 21:53 ч. UTC

Пазарно говорене

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1.06.2026 г., 21:22 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

1.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

1.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

1.06.2026 г., 20:46 ч. UTC

Придобивния, сливания и поглъщания

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1.06.2026 г., 20:22 ч. UTC

Придобивния, сливания и поглъщания

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1.06.2026 г., 20:21 ч. UTC

Придобивния, сливания и поглъщания

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1.06.2026 г., 20:21 ч. UTC

Придобивния, сливания и поглъщания

Array Digital Infrastructure Declares $11 Special Div

1.06.2026 г., 20:20 ч. UTC

Придобивния, сливания и поглъщания

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1.06.2026 г., 19:40 ч. UTC

Пазарно говорене

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1.06.2026 г., 19:28 ч. UTC

Пазарно говорене

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1.06.2026 г., 19:01 ч. UTC

Пазарно говорене

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1.06.2026 г., 18:58 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1.06.2026 г., 18:54 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1.06.2026 г., 18:33 ч. UTC

Пазарно говорене

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1.06.2026 г., 18:32 ч. UTC

Пазарно говорене

Precious Metals Fall to Start June -- Market Talk

1.06.2026 г., 18:00 ч. UTC

Придобивния, сливания и поглъщания

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1.06.2026 г., 17:18 ч. UTC

Пазарно говорене

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1.06.2026 г., 17:18 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.06.2026 г., 17:10 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Adaptive Biotechnologies Corp Прогноза

Ценова цел

By TipRanks

33.14% нагоре

12-месечна прогноза

Среден 20.17 USD 33.14%

Висок 22 USD

Нисък 18 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Adaptive Biotechnologies Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Adaptive Biotechnologies Corp през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.